Boston Scientific Corporation vs Utilities Select Sector SPDR Fund — how do they compare? Boston Scientific Corporation trades at $50.94 (market cap $74.19B), while Utilities Select Sector SPDR Fund trades at $43.8. The key difference: Utilities Select Sector SPDR Fund is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | XLU | |
|---|---|---|
Market Cap | $74.19B | — |
Sector | Health | — |
52-Week High | $108.14 | $47.73 |
52-Week Low | $42.63 | $41.31 |
Enterprise Value | $86.27B | — |
Signals from Pluang's Aura AI — not financial advice
BSX trades at $50.46, up 2.33% today, with strong earnings beats in recent quarters and a bullish technical trend. Revenue grew to $20.07B in 2025, with net income margin expanding to 17.5%. The stock shows robust institutional support and insider buying, while facing near-term headwinds from competitive pressures in key segments like WATCHMAN.
Outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target, implying 33% upside. Risks include guidance cuts and market share losses, but solid cash flow and valuation metrics support long-term growth potential for patient investors.
XLU trades at $43.74, up 1.39% with bearish technical signals from moving averages and oscillators. The ETF shows strong institutional call option activity, with 43,489 contracts traded on August 11, 2026, representing an 18% increase over typical volume. Recent news highlights XLU's positioning as an AI power demand play, with utilities gaining attention for data center electricity needs. The fund offers defensive income characteristics with dividend distributions scheduled for June 2026.
XLU faces technical headwinds but benefits from structural AI power demand growth. The ETF's defensive utility holdings provide income stability while capturing electricity infrastructure expansion. Key risks include interest rate sensitivity and regulatory changes, but institutional interest in call options suggests bullish positioning on the AI power theme.
Trailing returns across standard periods
Latest headlines on both assets
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Read more on XLU →